UiPath (PATH) Slides As Analysts Slash Price Targets

UiPath Inc. stocks have been trading down by -6.93 percent amid investor concerns over softer automation demand and revenue growth.

Live Update At 15:02:09 EDT: On Friday, October 16, 2026 UiPath Inc. stock [NYSE: PATH] is trending down by -6.93%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

PATH is trading like a name under pressure. Over the last few weeks, UiPath stock has slipped from the mid-$13s to around $12.76, with the latest daily candle on 2026/10/16 showing a failed morning push to $14 and a close near the lows. That’s classic distribution behavior: strength gets sold.

On the intraday 5‑minute chart, PATH shows a steady fade from the open, with lower highs all day and no real bounce into the close. For short‑term traders, that intraday pattern confirms sellers remain in control and dip-buying is not sticking yet.

Fundamentally, UiPath is not a broken business. The company printed about $1.61B in revenue over the last year, with a hefty 82.6% gross margin and positive EBIT margin of 10.4%. PATH throws off free cash flow — about $29.3M in the latest reported quarter — and carries very little debt, with total‑debt‑to‑equity at just 0.04 and a current ratio of 2.4. But the stock is not cheap on cash flow, with price‑to‑free‑cash near 60 and price‑to‑sales around 4. That valuation demands real growth, which is exactly what the Street is starting to doubt.

Why Traders Are Watching PATH Now

PATH is sitting right in the crosshairs of hype versus proof. UiPath sells automation and AI‑driven software — the kind of story that usually commands big multiples. Yet the latest analyst moves show confidence is getting reset lower.

The key shock came on 2026/09/28, when DA Davidson downgraded PATH from Neutral to Underperform and slashed its target to $10. That level sits well below both the average Street target in the mid‑teens and the recent trading zone around $12–$14. The firm pointed to mixed customer and partner feedback after UiPath’s Investor Day and pushback on AI pricing. For traders, that screams risk to both demand quality and pricing power.

Other banks piled on. UBS cut its UiPath price target to $14 and explicitly questioned whether buzzy products like Coding Agents can drive more than roughly 10% annual recurring revenue growth by FY28. BMO clipped its PATH target from $18 to $15, calling out the lack of long‑term ARR guidance and weaker platform attach rates even as competition in automation heats up. RBC lowered its target to $15 and kept PATH in the “show‑me” bucket — the Street wants evidence, not just decks.

The near‑term reaction has been clear. After DA Davidson’s downgrade and $10 target, PATH dropped about 2%, reinforcing the idea that analyst cuts are not just noise. Yet the broader Street still sits at Hold with average targets around $15–$16. That means expectations are being reset, not abandoned. For active traders, this mix — negative headlines, lowered bars, and a still‑crowded neutral camp — often sets up strong trend moves once the next catalyst hits.

Conclusion

PATH is at an important crossroads where narrative and numbers have to reconnect. On one side, UiPath’s financials show a real business: strong gross margins, positive operating income, solid cash, and minimal leverage. On the other side, multiple firms now question whether PATH can turn its automation and AI pitch into the kind of long‑term ARR growth the current valuation implies.

For swing traders, the $10–$15 band defined by DA Davidson on the downside and the Street’s mid‑teens averages on the upside marks the key battleground. A decisive break below the recent $12–$13 zone with volume would confirm that the downgrade cycle is driving a new leg lower. A strong rebound through $14–$15, backed by improving ARR trends, would say UiPath is starting to “show” rather than just “tell.”

Short‑term, the intraday fade and recent closing weakness keep PATH in “guilty until proven innocent” territory. That’s where discipline matters most. As Tim Sykes likes to say, “The market doesn’t care about your opinion, only about price and volume — respect that or pay the price.” As millionaire penny stock trader and teacher Tim Sykes says, “Cut losses quickly, let profits ride, and don’t overtrade.” For traders studying PATH now, the job is to track those levels, watch how the stock reacts to any new data, and stay ruthless about risk — this is educational analysis, not a signal to buy or sell.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks